Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…-responders and in particular the timing and dosing schedule of infliximab.In addition, we explore other approaches including use of Janus…
…Vedolizumab and Ustekinumab were first approved by our trust for treatment of patients with…
…(11%), with two commencing or escalating biologics (infliximab, vedolizumab) and one receiving a non-biologic adjustment. No surgical refer…
… receiving biologic therapy at the time of the audit, including infliximab in 47, adalimumab in 13, ustekinumab in 2, and vedolizumab in 1…
…onstrated variable mucosal inflammation. Symptoms improved with leflunomide and low-dose prednisolone, but were non-responsive to inflixima…
…4S1) was made. The patient was started on Anti-TNF α treatment (Infliximab 10 mg/kg) on an accelerated regimen 0,1 and 5 weeks . He was di…
…isease (IBD) exhibit non-response to biologic therapies such as infliximab (IFX), underscoring the need for combination strategies. Ferrop…
…b 44.3%, Adalimumab 27.9%, Vedolizumab 13.1%, Ustekinumab 9.8%, Golimumab 3.3% and Risankizumab 1.6%.The mean [±SD] gestational age at tr…
…IBD patients in stable remission on combination therapy with IV IFX and TP can be safely switched to SC IFX without the need for co…
…fined. TM1 (n=325 genes) enrichment associated most highly with ustekinumab resistance (Spearman rank correlation, ρ: -0.26), along with TM…
…ommon recent drugs were adalimumab, infliximab, ustekinumab and vedolizumab. There were no significant differences between groups in potent…
…ctors associated with obesity in patients with IBD treated with infliximab and vedolizumab across the United Kingdom (UK). Gut 2025;74:A12…